The current WHO grading of central nervous system tumors relies exclusively on histopathological criteria for diagnosing lower-grade, IDH-mutant astrocytomas (LGIMAs), overlooking genetic features. Here, IDH2 is linked to astrocytoma (excluding glioblastoma).